iScience (Jul 2023)

Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity

  • Taojun Ye,
  • Anqi Lin,
  • Zhengang Qiu,
  • Shulu Hu,
  • Chaozheng Zhou,
  • Zaoqu Liu,
  • Quan Cheng,
  • Jian Zhang,
  • Peng Luo

Journal volume & issue
Vol. 26, no. 7
p. 107045

Abstract

Read online

Summary: There is an urgent need for markers to predict the efficacy of different chemotherapy drugs. Herein, we examined whether microsatellite instability (MSI) status can predict tumor multidrug sensitivity and explored the underlying mechanisms. We downloaded data from several public databases. Drug sensitivity was compared between the high microsatellite instability (MSI-H) and microsatellite-stable/low microsatellite instability (MSS/MSI-L) groups. In addition, we performed pathway enrichment analysis and cellular chemosensitivity assays to explore the mechanisms by which MSI status may affect drug sensitivity and assessed the differences between drug-treated and control cell lines. We found that multiple MSI-H tumors were more sensitive to a variety of chemotherapy drugs than MSS/MSI-L tumors, and especially for CRC, chemosensitivity is enhanced through the downregulation of DDR pathways such as NHEJ. Additional DNA damage caused by chemotherapeutic drugs results in further downregulation of DDR pathways and enhances drug sensitivity, forming a cycle of increasing drug sensitivity.

Keywords